STARTUP PROFILE

Paradromics

COUNTRY
USA
FOUNDED
2016
CATEGORY
Brain-Computer Interface
Developing the Connexus, a fully implantable, high–data-rate BCI that records single-neuron brain signals to restore communication in paralyzed patients.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series B
MODALITY
Intracortical
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Communication
TARGET USER
Patients
REGULATORY STAGE
Investigational
Paradromics is one of the most serious competitors in the high-bandwidth implantable BCI category, emphasizing single-neuron recording and communication restoration. It is often framed as a peer to Neuralink, though with a more tightly defined initial use case and lower public visibility.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

Paradromics received FDA approval to recruit nationwide for its Connect-One feasibility study, removing the requirement to live within four hours of a clinical site. Eligible participants from across the US can now travel to one of the three US sites. A week before, the company announced a collaboration with Siemens Healthineers to develop an integrated imaging workflow for BCI patients, from surgical planning to implant placement.

#
11
BCI reaches a new scale
30 September – 13 October 2026

Paradromics reported more than four years of stable neural recordings in two sheep implanted with electrodes representative of its Connexus BCI. Signal quality remained steady without electrode migration, while a separate six-sheep study of the full platform is approaching two years of stability. The findings support its long-term durability work as Paradromics advances its Connect-One human feasibility study for speech restoration.

Articles featuring
Paradromics